Abstract Background and Aims Vaccines are the first line of defense against coronavirus
disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid …

Here we report on the most recent updates on experimental drugs successfully employed in
the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as COVID …

This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …

Nirmatrelvir plus ritonavir (Paxlovid™; Pfizer) is a co-packaged combination of nirmatrelvir
and ritonavir tablets, intended for co-administration and developed for the treatment and …

A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome
(SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly …

Sir, A novel coronavirus, SARS-CoV-2, emerged in December 2019 in Wuhan, China, which
is spreading far more rapidly than its predecessors, having already infected millions of …

Background. Several drugs which are easy to administer in outpatient settings have been
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …

The rising outbreak of SARS-CoV-2 continues to unfold all over the world. The development
of novel effective antiviral drugs to fight against SARS-CoV-2 is a time cost. As a result, some …

An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID‐2019. In addition to the recommended …

Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir
and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials …